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Chronic painComplex regional pain syndrome (CRPS) is a chronic pain disorder that typically follows trauma or surgery.
Suspected CRPS reported after vaccination with human papillomavirus (HPV) vaccines led to temporary suspen-
sion of proactive recommendation of HPV vaccination in Japan. We investigated the potential CRPS signal in re-
lation to HPV-16/18-adjuvanted vaccine (Cervarix®) by database review of CRPS cases with independent expert
confirmation; a disproportionality analysis and analyses of temporality; an observed versus expected analysis
using published background incidence rates; systematic reviews of aggregate safety data, and a literature review.
The analysis included 17 case reports of CRPS: 10 from Japan (0.14/100,000doses distributed) and seven from the
United Kingdom (0.08/100,000). Five cases were considered by independent experts to be confirmed CRPS.
Quantitative analyses did not suggest an association between CRPS and HPV-16/18-adjuvanted vaccine.
Observed CRPS incidence after HPV-16/18 vaccination was statistically significantly below expected rates.
Systematic database reviews using search terms varying in specificity and sensitivity did not identify new
cases. No CRPS was reported during clinical development and no unexpected results found in the literature.
There is not sufficient evidence to suggest an increased risk of developing CRPS following vaccination with HPV-
16/18-adjuvanted vaccine. Post-licensure safety surveillance confirms the acceptable benefit-risk of HPV-16/18
vaccination.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Complex Regional Pain Syndrome (CRPS) is a chronic pain disorder
characterised by significant autonomic features, and typically develops
in an extremity after acute tissue trauma (Merksey & Bogduk, 1994).
Symptoms may include continuing pain, sensory abnormalities like
allodynia and/or, hyperalgesia and/or hypoesthesia, along with a range
of vasomotor (abnormalities in skin colour or temperature), sudomotor
(abnormalities of sweating or oedema) andmotor/trophic (abnormalities
in hair, skin, nails, tremor or muscle weakness) signs or symptoms.
The estimated incidence of CRPS varies from5.46 to 26.2 per 100,000
person-years, with an incidence in females of 8.57 to 40.4 per 100,000
person-years (De Mos et al., 2007; Sandroni et al., 2003). CRPS occurs
slightly more often in the upper extremity and women are affectedasmus MC, University Hospital,
. This is an open access article under3.4–4 times more often than men (De Mos et al., 2007). Diagnosis is
based upon clinical criteria. Themost commonly used diagnostic criteria
are modifications to the original International Association for the Study
of Pain (IASP) criteria according to Harden and Bruehl (Budapest diag-
nostic criteria) (Harden et al., 2010).
The pathophysiology of CRPS continues to be debated in the literature.
Current understanding implicates peripheral, afferent, efferent and cen-
tral mechanisms (Van Eijs et al., 2011). There are indications that auto-
inflammatory and/or genetic predisposition (for example, polymor-
phisms of human leucocyte antigen (Kemler et al., 1999; Mailis & Wade,
1994; Van de Beek et al., 2003; Van Hilten et al., 2000; De Rooij et al.,
2009a; Dirckx et al., 2015), TNF-alpha (Vaneker et al., 2002), or possibly
angiotensin-converting enzyme gene (Hühne et al., 2004; Kimura et al.,
2000) play a role in the pathophysiology (De Rooij et al., 2009b; Goebel
& Blaes, 2013). Associations have been suggested between CRPS and ex-
posure to some viruses and or bacteria, such as parvovirus B19, herpes
simplex virus, Campylobacter jejuni, Borrelia burgdorferi, and spirochetes
(Van de Vusse et al., 2001; Muneshige et al., 2003; Goebel et al., 2005;the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
MedDRA terms used to identify potential unrecognised CRPS cases in the safety database.
Proposed clinical diagnostic criteria for CRPS
(Budapest criteria)(Harden et al., 2010)⁎
MedDRA
Preferred terms or low level terms
Pain: continuing pain disproportionate
to vaccination
Pain; pain in extremity
Sensory: allodynia deep pressure pain,
allodynia pain after movement,
allodynia after light touch,
hyperesthesia, hypoesthesia,
hyperalgesia, hypoalgesia
Allodynia, hyperaesthesia,
hypoaesthesia, sensory
disturbance, skin burning
sensation
Vasomotor: color change/difference,
temperature difference
Skin discoloration, temperature
difference of extremities
Sudomotor/edema: transpiration disturbance,
edema
Oedema
Trophic: hair growth change,
nail growth change,
trophic skin disturbance
Hair growth abnormal,
nail growth abnormal
Motor: limitation of movement,
limitation of strength, dystonia,
tremor, bradykinesia
Injection site movement
impairment, injected limb
mobility decreased, muscular
weakness, dystonia, tremor,
bradykinesia
⁎ Pain should be continuous and disproportionate to the inciting event. In addition, for
clinical diagnosis patients should have at least one symptom in each of the above catego-
ries and one sign in one category.
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(Jastaniah et al., 2003; Genc et al., 2005).
HPV-16/18-adjuvanted vaccine (Cervarix®, GSK Vaccines, Belgium)
was first licenced in 2007 and is currently licenced in 134 countries
for the prevention of persistent infection, pre-cancerous lesions, and
cervical and other genital cancers caused by oncogenic HPV. In March
2013 the Japanese press reported the case of a 14-year-old girl who
had been diagnosed with CRPS in 2011, with onset of symptoms hours
after vaccination with HPV-16/18-adjuvanted vaccine in 2009. The
case generated significant media reporting in Japan (Wilson et al.,
2014). An anti-vaccines group publicly called into question the safety
of HPV vaccination and the Japanese national immunisation pro-
gramme. At meetings held inMay and June 2013, the Japanese Ministry
of Health, Labor and Welfare (MHLW) publicly concluded that they
found no reason for concern, but temporarily suspended proactive rec-
ommendation of vaccination for both available HPV vaccines in Japan
(Cervarix® and Gardasil™ [HPV-6/11/16/18 vaccine, Merck & Co.])
until more information was available. HPV vaccination remains part of
the Japanese government-funded vaccine programme and physicians
can continue vaccination after explanation of benefit-risk.
Here we report the results of analyses undertaken by GSK Vaccines
to investigate the potential CRPS signal. These investigations comprise
a review of individual case reports (including an independent evalua-
tion by an external expert panel), quantitative analyses assessingpoten-
tial associations, systematic reviews of aggregate safety data and a
literature review. These data provide a comprehensive assessment of
safety information pertaining to HPV-16/18-adjuvanted vaccine and
CRPS, thereby facilitating informed decision-making by vaccine pro-
viders and recipients.
2. Methods
GSK Vaccines follows a systematic approach to safety assessment,
which includes regular review of individual case reports and aggregate
data based on database searches from adverse event (AE) reports re-
ceived by the company (Angelo et al., 2014a). Reports of AEs after vac-
cination are received by GSK through spontaneous reporting via
worldwide sources from healthcare professionals, regulatory authori-
ties, members of the public, and literature sources. All spontaneously re-
ported AEs are coded in GSK's central worldwide safety database using
the International Conference on Harmonisation Medical Dictionary for
Regulatory Activities (MedDRA) to the level of preferred term (PT)
(Medical Dictionary for Regulatory Activities, 2015). For cases where
important clinical details are lacking, attempts are made to contact the
source for additional information.
2.1. Primary Analyses
2.1.1. Qualitative Analyses
All spontaneous reportswithHPV-16/18-adjuvanted vaccine (or un-
specified HPV vaccine) reported as suspect and containing the specific
MedDRA PT ‘complex regional pain syndrome’ were identified from
launch until the data lock point of 31 July 2013.
Identified cases were reviewed according to the proposed experi-
mental IASP criteria (Harden et al., 1999) by a safety physician within
GSK (JZ). Two independent external experts (FH and CM) were provid-
ed with the individual clinical narratives of identified cases for review
using Budapest diagnostic criteria (Harden et al., 2010). The assessment
of cases by GSK and the results of the quantitative analyses were only
sharedwith the experts once their own separate assessments of individ-
ual cases were completed.
2.1.2. Quantitative Analyses
A disproportionality analysis provided information on the frequency
of reporting of a vaccine-event pair relative to background reporting in
the database (Van Holle et al., 2012; Karimi et al., 2013), aiming todetect higher than expected reporting of vaccine-event combinations.
The analysis used anempirical Bayes datamining algorithm(Multi-Item
Gamma Poisson Shrinker) which computed the adjusted relative
reporting ratio and associated 90% confidence intervals (CI) stratifying
for age, gender, calendar time period and region.
An analysis of temporality was performed to detect potential
differences in the reported temporal time-to-onset distributions of
CRPS post-HPV-16/18 vaccination, versus post-other injected GSK
Vaccines. This analysis assumed that for other injected vaccines, the
time-to-onset distribution of CRPS was dominated by reporting bias
and noise. Thus, a different time-to-onset distribution post-HPV-16/18
vaccination could suggest a potential temporal association between
HPV-16/18-adjuvanted vaccine and CRPS (Van Holle et al., 2012;
Karimi et al., 2013). The time-to-onset distribution of HPV-16/18-
adjuvanted vaccine-CRPS was tested with a two-sample Kolmogorov
Smirnov test over a 30 day period post-immunisation.
An observed-versus-expected analysis used background incidence
rates from the available published literature to calculate age-adjusted
expected incidence rates with CI provided using a Monte-Carlo simula-
tion. HPV-16/18-adjuvanted vaccine exposure was estimated based on
the number of doses sold. There is no acknowledged risk period for
CRPS after a precipitating event. While reports of possible CRPS after
vaccination have occurred on the same day as the vaccination
(Jastaniah et al., 2003; Genc et al., 2005), we considered a theoretical
risk window of six days after vaccination. The observed-versus-
expected analysis was conducted separately for Japan, the UK and
worldwide.
2.2. Extended Analyses
(1) There is little information on background incidence rates of CRPS
and the proportion of cases that might be underreported is not
known. The observed-versus-expected analysis was therefore
extended by a set of simulations that considered a range of
reporting rates and background incidence rates to establish
underreporting magnitudes and incidence rates for which the
observed number of CRPS cases can be considered as expected
for Japan, the UK and worldwide.
(2) To investigate the possibility that CRPS after HPV-16/18 vaccina-
tion has occurred but gone unrecognised, an additional database
search identified all spontaneous reports with MedDRA PTs de-
scribing signs and symptoms associated with CRPS mapped to
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Reports were retrieved from launch until 31 December 2013
and were restricted to those in which an HPV vaccine had been
administered. A decision tree was used to improve diagnostic
precision: cases were categorised based on whether they includ-
ed theMedDRAPTs of ‘pain’ or ‘pain in extremity’ in combination
with another associated symptom, and whether the duration of
pain was more than two weeks (Fig. 1).
(3) As the MHLW conducted a similar search of locally reported
cases but excluded cases where ‘pain’ was associated with
other events, the company conducted a similar analysis. A
broader evaluation of the safety data around pain (notably
chronic pain) following HPV vaccination was undertaken. All
cases under the MedDRA system organ classes (SOC) “musculo-
skeletal and connective tissue disorders” or “general disorders
and administration site conditions” with a MedDRA PT of ‘pain’
were retrieved and analysed.2.3. Role of the Funding Source
GlaxoSmithKline Biologicals SA collected and analysed the data. All
authors had access to the data, responsibility for data interpretation,
and the decision to submit for publication.3. Results
At the time of the data lock point for this manuscript, there were
221,220 spontaneous adverse event reports in GSK's vaccines safety da-
tabase, of which 18,391 were reported for HPV-16/18-adjuvanted vac-
cine. The 10 countries from where the most spontaneous event reports
for HPV-16/18-adjuvanted vaccine originated were: Japan 32% of all re-
ports, Italy 20%, Malaysia 16%, UK 11%, Netherlands 5%, Germany 2%,
Korea 2%, Spain, Brazil and the US all 1%. Note that the reporting rate is
influenced by the number of doses distributed in each country, as well
as the robustness and efficiency of the pharmacovigilance systems and
awareness of adverse event reporting tools in place.Fig. 1. Schematic representation of search strategy and breakdown of selected cases. The safet
From this dataset, cases were selected reporting pain and/or pain in extremity (n = 1616) wh
with unspecified event duration (n = 231). Cases reporting the MedDRA PT of CRPS (n = 9) w
for further evaluation reported pain together with motor disturbances. Refer to boxes highligh3.1. Reports of CRPS
3.1.1. Analysis of CRPS Cases by GSK
The first database search retrieved 17 case reports with the PT ‘com-
plex regional pain syndrome’, with seven cases from the UK and 10
cases from Japan, corresponding to reporting rates of 0.08 and 0.14
cases per 100,000 doses distributed, respectively. The number of HPV-
16/18-adjuvanted vaccine doses distributed worldwide each month
has remained relatively stable since June 2008 (Fig. 2). Six CRPS cases
(35% of all reports) were received after the initial case in Japan was re-
ported in the media in March 2013 (Wilson et al., 2014).
The time between vaccination and the onset of symptoms ranged
from immediately after vaccination to two years post-vaccination
(Table 2). The diagnostic criteria for CRPS were met for 4/17 events: of
these, one subject also received Japanese encephalitis vaccine before
symptom onset, and one subject developed subacromal bursitis due to
maladministration of the product. Seven cases were assessed as uncon-
firmed CRPS and six cases as unlikely to be CRPS based on the available
information (Supplementary table 1).
Results of quantitative analyses: few background CRPS incidence
data were retrieved. These were limited to two countries: the US and
the Netherlands (Van Holle et al., 2012; Karimi et al., 2013). The results
of the disproportionality analysis did not suggest that the vaccine-event
pair (HPV-16/18-adjuvanted vaccine and CRPS) was reported at a
higher-than-expected rate relative to background reporting in the data-
base (adjusted relative reporting stratified Empirical Bayes Geometric
Mean of 1.018, 90% CI 0.703–1.435). The time-to-onset was known for
seven HPV-16/18 cases with CRPS and for 13 cases retrieved for other
injected vaccines. No significant difference in the time-to-onset distri-
bution was observed (p-value 0.78).
Thirteen cases with a time-to-onset unknown or within six days
after vaccination were included in the observed-versus-expected
analysis (Table 3). Under the assumption that 100% of CRPS cases with
time-to-onset within six days post-HPV-16/18 vaccination have been
reported, the observed incidence rates were below expected rates, ex-
cept under a worst case scenario for the UK and Japan, when all cases
(confirmed/unconfirmed/unlikely) were included. Under these condi-
tions the point estimates for the observed incidence rates were higher
than the expected background incidence rates calculated from US datay database was searched for cases reporting any of the selected MedDRA PTs (n = 2730).
ich was further narrowed down by identifying cases reporting a duration of ≥2 weeks or
ere not further considered as they were evaluated separately. Most of the cases retained
ted in grey for breakdown of cases according to the combination of events reported.
Fig. 2. Spontaneous reports of CRPS (n = 16*) and number of doses distributed each month since launch of HPV-16/18-adjuvanted vaccine. *Following the initial analysis, one of the 17
originally identified CRPS cases was voided as the girl had received Gardasil™. Hence this case is not shown. Note that HPV-16/18-adjuvanted vaccine was licenced in the UK two years
before it was licenced in Japan.
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(Table 3).
Fig. 3 shows results for the observed-versus-expected analysis using
a simulated range of background incidence rates and underreporting.
Considering a worst case safety scenario with inclusion of all cases
(confirmed/unconfirmed/unlikely) the simulations indicated that for
Japan, the observed rates would be significantly higher than expected
rates under the assumption that less than 60% of cases were reported
when comparing to US background incidence data, and that less than
approximately 10% were reported when comparing to data from the
Netherlands (Fig. 3). Results for the UK were 83% and 13%, respectively
(Fig. 3).
3.1.2. Analysis of CRPS Cases by an Independent Expert Panel
Discrepancies noted between the experts' assessment and GSK's
evaluation were discussed individually at a face-to-face meeting for
clarification and consensus. The experts concurred in their independent
analysis identifying five confirmed CRPS cases among the 17 reports
(Supplementary table 1).
3.1.3. Reports Describing Signs/and Symptoms Associated With CRPS
A total of 2730 spontaneously reported cases reporting any, or a
combination of MedDRA PTs describing signs/symptoms associated
with CRPS (but excluding the specific PT ‘complex regional pain syn-
drome’) (Table 1) were retrieved from the GSK spontaneous report da-
tabase. The decision tree to improve diagnostic precision led to
identification of 231 potential cases (Fig. 1). For 221 cases the duration
of pain was not specified. For 10 cases where the duration of pain wasTable 2
Summary information of 17 reports of CRPS identified in GSK's safety database.
Case details N = 17 CRPS casesa
Age (years) Median (range) 13 (12–46)
Report source n (%)b Health care professional 17
Regulatory authority 9
Other 8
Time to onset Range Immediate to 2 years
post-vaccination
Outcome n (%) Resolved 4 (23%)
Resolved with sequelae 1 (6%)
Unresolved 3 (18%)
Worse 1 (6%)
Unknown 8 (47%)
a Cases identified by searching all spontaneous reports for cases containing the specific
MedDRA preferred term CRPS from launch until 31 July 2013.
b Some cases were reported by more than one source.two weeks or more, the reported MedDRA PTs were hypoaesthesia
(n = 4), injected limb mobility decreased (n = 4), muscular weakness
(n = 5), sensory disturbance (n = 1) and skin discoloration (n = 1).
Considering the specific features of pain reported by these subjects,
none presented a clinical picture suggestive of a potential CRPS case.
The 221 cases without information on pain duration were individu-
ally assessed. The majority of cases reported MedDRA PTs indicative of
motor disturbances with decreased mobility of the injected limb and
muscular weakness: most cases reported injection site pain that
prevented movement of the injected limb. The most frequently report-
ed sensory AE was hypoaesthesia, with symptom onset, together with
pain, soon after vaccination.
No cases indicative of unrecognised CRPSwere identified. Thenature
of the cases and/or the information contained in the case reports did not
add new information to the conclusions reached following review of 17
cases reporting the MedDRA PT of ‘complex regional pain syndrome’
itself.
Eleven additional reports of CRPS have been received from Japan
since the data lock point of the previous analysis described above.
None met the Budapest diagnostic criteria of CRPS as assessed by GSK
(Supplementary table 2).
3.1.4. Reports Describing Chronic Pain
A total of 3103 spontaneously reported cases with HPV-16/18-
adjuvanted vaccine or unspecified HPV vaccine as suspect vaccine
were retrieved using the search criteria. The majority of reports came
from Japan (31%), Italy (25%), Malaysia and UK (each 11%) and the
Netherlands (7%), with 15% from other countries. The highest reporting
ratewas from Italy (38/100,000 doses distributed) andMalaysia and the
Netherlands (each 15/100,000 doses) followed by Japan (14/100,000
doses distributed). The most frequently occurring PTs were myalgia
(n = 1077 reports), pain (n = 912), pain in extremity (n = 650) and
arthralgia (n = 538) (Fig.4). Because there is a theoretical risk that
adjuvanted vaccines may trigger the onset of immune-mediated dis-
eases in susceptible individuals, cases that contained aMedDRAPT indi-
cating a potential immune-mediated disease (pIMD) were identified in
this dataset (Tavares Da Silva et al., 2013). There were 59 cases with a
pIMD covering eight SOCs and 27 different MedDRA PTs. Considering
reports from Japan, no pattern or symptom cluster was apparent in
comparison to global reports.
Of 3103 retrieved cases, the time-to-onset and duration of pain was
known in 1093 (Fig.4). Individual review of themost frequently report-
ed PTs with known time-to-onset and pain duration of at least two
weeks did not show any consistent pattern in terms of the clinical pic-
ture, or a safety signal in association with HPV-16/18 vaccination.
Table 3
Observed versus expected analysis of CRPS cases after HPV-16/18 vaccination.
Observed Expected-simulated age-adjusted incidence/100,000
person-years (95% CI)
Number of cases Incidence/100,000 person-years (95% CI) Sandroni et al. (2003)
United States
De Mos et al. (2007)
The Netherlands
Worldwide Confirmed CRPS with known time-to-onset 3 0.4 (0.1; 1.3) 2.8 (0.9; 5.7) 16.4 (7.9; 26.4)
All cases: confirmed/unconfirmed/unlikely 13 1.9 (1.0; 3.3) 2.8 (0.9; 5.7) 16.4 (7.9; 26.4)
Japan Confirmed CRPS with known time-to-onset 1 0.9 (0.0; 4.8) 3.1 (1.1; 6.0) 16.9 (9.5; 26.0)
All cases: confirmed/unconfirmed/unlikely 6 5.2 (1.9; 11.3) 3.1 (1.1; 6.0) 16.9 (9.5; 26.0)
UK Confirmed CRPS with known time-to-onset 2 1.4 (0.2; 5.1) 2.4 (0.3; 5.6) 15.3 (6.5; 26.3)
All cases: confirmed/unconfirmed/unlikely 7 4.9 (2.0; 10.2) 2.4 (0.3; 5.6) 15.3 (6.5; 26.3)
CI = confidence interval.
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was associatedwith other diagnoses (as perMHLWcriteria)was broad-
ly consistent with the larger analysis.
3.1.5. CRPS Reported in Clinical Trials
A pooled safety analysis included data from all completed and ongo-
ing studies in which HPV-16/18-adjuvanted vaccine had been adminis-
tered to females from 9 years of age until the data lock point of 30 April
2011 (Angelo et al., 2014b). This analysis included 31,173 girls and
women who received HPV-16/18-adjuvanted vaccine and 24,241 who
received a control (placebo or comparator vaccine). No reports of
CRPS were identified from clinical trials.
4. Discussion
Rigorous review of all potential CRPS cases reported to GSK since
launch of HPV-16/18-adjuvanted vaccine identified five cases consid-
ered by independent experts to be confirmed CRPS. Considering all
five cases globally, the reporting rate is 0.01 cases per 100,000 doses dis-
tributed. Quantitative analyses did not suggest a higher CRPS reporting
rate after HPV-16/18-adjuvanted vaccine than after other vaccines, nor
a temporal relationship with HPV-16/18-adjuvanted vaccine that
differed from other vaccines. An observed-versus-expected analysis
suggested that the observed incidence rate of CRPS after HPV-16/18-
adjuvanted vaccine is not significantly higher than the expected rate
for a range of plausible combinations of background incidence rate
and reporting bias. Detailed systematic reviews of the central world-
wide safety database using search terms varying in specificity and sen-
sitivity did not add new information to the conclusions reached
following review of cases reporting the MedDRA PT of CRPS. There
was no report of CRPS in the overall clinical trial programme.
Regular review of spontaneous adverse event reports enables the
detection of safety signals during the lifecycle of a vaccine. However,
in most countries adverse event reporting is passive, and adverse
event reporting rates are highly variable, influenced by awareness and
ease of use of the adverse event reporting systems, cultural expecta-
tions, experience with the vaccine or with similar vaccines, characteris-
tics and severity of the adverse event itself, the period of timewhich has
elapsed since the vaccination procedure and onset of symptoms, and
external factors such as media reports (Eberth et al., 2014). Indeed, in-
creased reporting of suspected CRPS cases in Japan coincided with ex-
tensive media coverage of a CRPS case in Japan (Wilson et al., 2014).
Aside from the limitations inherent in analysis of spontaneous adverse
event reports, our analyses are limited by the condition itself: CRPS is
an incompletely understood syndrome made up of a cluster of hetero-
geneous symptoms, many of which are non-specific. No diagnostic
test is available, the list of differential diagnoses is extensive and there
is little available information on background incidence rates in the
literature. We conducted simulations to estimate howmaking assump-
tions on the underreporting and the background incidence rate of CRPScould affect the conclusions of the observed-versus-expected analysis.
The results from these simulations allow experts to draw their own con-
clusions by applying, based on their knowledge, the most appropriate
value for the two main sources of uncertainty affecting the observed-
versus-expected analysis (Fig. 3). A constraint of these simulations is
that they are limited to the two factors that were deemed as the main
source of uncertainty (underreporting and background incidence).
Other potential sources of uncertainty (e.g., the true risk window
length) were not assessed.
Assessments of CRPS and HPV-16/18-adjuvanted vaccine have been
conducted independently by regulatory agencies. In December 2012 the
UK Medicines and Healthcare products Regulatory Agency (MHRA)
published an observed-versus-expected analysis and a safety assess-
ment report after 4 years of HPV-16/18-adjuvanted vaccine use in the
UK (Medicines and Healthcare products Regulatory Agency (MHRA),
2012). The report concluded that “Reported cases of CRPS are consistent
with chance and there is insufficient evidence of a causal association with
Cervarix” (Medicines and Healthcare products Regulatory Agency
(MHRA), 2012). The World Health Organization's Global Advisory
Committee on Vaccine Safety could not ascertain a causal relationship
of CRPS to HPV vaccination given lack of sufficient case information
and inability to reach a definitive diagnosis in many cases (Global
Advisory Committee on Vaccine Safety, 2013). Finally, in April 2014
after review of cumulative data, quantitative analyses and database
searches provided by GSK, the European Medicines Agency concluded
that the available data do not support a causal relationship between
the use of HPV-16/18-adjuvanted vaccine and CRPS onset at this stage
(EMA European Medicines Agency, 2014). CRPS remains under close
surveillance.
We identified two case-series of CRPS after HPV vaccination in the
literature. One article described peripheral sympathetic nerve dysfunc-
tion in 40 adolescent Japanese girls following immunisation with HPV
vaccine (Kinoshita et al., 2014). According to the authors, four girls ful-
filled the Japanese clinical diagnostic criteria of CRPS-1 (CRPS without
known major nerve injury), and 14 fulfilled the Budapest diagnostic
criteria (Harden et al., 2007). The paper describes five representative
case reports. However, based on the case descriptions, none fulfil either
of the CRPS diagnostic criteria (Japanese or Budapest); which raises the
question of how the diagnostic criteria were applied. The authors also
describe a postural orthostatic tachycardia syndrome (POTS), orthostat-
ic hypotension (OH) and lowplasma levels of noradrenaline in somepa-
tients. Whereas low levels of noradrenaline are described in CRPS, POTS
and OH are not general findings in CRPS. Moreover, the sympathetic
dysfunction is typically local and distal in one of the extremities and in
no way general (Wasner, 2010), as seems to be the case with the girls
described in the article.
The second article described five CRPS cases that the authors state
fulfilled Budapest diagnostic criteria (Harden et al., 2007): four cases
followed HPV vaccination (HPV-16/18-adjuvanted vaccine or HPV-6/
11/16/18 vaccine ) and one followed diphtheria–tetanus–pertussis
Japan
United Kingdom
Fig. 3.Heat maps of the observed-to-expected analysis conclusion in the parameter plane defined by the background incidence rate and the under-reporting (two unknown parameters).
Risk period of six days post HPV-16/18 immunisation and considering all cases irrespective of whether classified as confirmed/unconfirmed or unlikely to be CRPS.
1119F. Huygen et al. / EBioMedicine 2 (2015) 1114–1121vaccine (Richards et al., 2012). In view of the different antigens admin-
istered, the authors proposed that the intramuscular injection was the
event trigger, rather than the vaccine antigens themselves.
It remains unknown whether the development of CRPS could occur
as an indirect effect of tissue trauma following injection of vaccine, or
through an auto-inflammatory response, triggered by infection (or ex-
posure to vaccine antigens) in susceptible individuals. The frequency
of CRPS is so low compared to the frequency of infections, that the lattercan be considered unlikely to play a pivotal etiological role. More obvi-
ously, the method of (injectable) vaccine administration is a procedure
that initiates local tissue damage, which is acknowledged as amain trig-
ger for a maladaptive and persistent response that continues after
healing, which is pathophysiologic and characteristic for CRPS.
Altogether, based on the outcomes of this valuation, there is not suf-
ficient evidence to suggest an increased risk of developing CRPS follow-
ing vaccination with HPV-16/18-adjuvanted vaccine. Post-licensure
18,391 total spontaneous adverse event reports searched for 
HPV-16/18-adjuvanted vaccine from global sources
3103 cases retrieved that contain MedDRA PTs indicative of 
chronic pain (Table 1) 
1093 reports with known date of onset (range 0-300 days after 
vaccination) and duration (range 0-538 days) of symptoms
Myalgia (N=542): individual review of 34 cases with duration 
>14 days  
Arthralgia (N=205): individual review of 17 cases with duration 
>14 days  
Pain in extremity (N=185): individual review of 15 cases with 
duration >14 days  
Pain (N=165): individual review of 14 cases with duration >14 
days  
Fig. 4. Flow digram illustrating the assessment of potential cases with chronic pain.
1120 F. Huygen et al. / EBioMedicine 2 (2015) 1114–1121safety surveillance confirms the acceptable benefit-risk of HPV vaccina-
tion in adolescent girls and adult women (Angelo et al., 2014a).
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